报价延迟最少15分钟:2025/11/19 11:06 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.74 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.57/-4.57
|
|
企业价值
388.74M
|
| 资产负债 |
|
每股账面净值
8.91
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
210.78M
|
|
每股收益
2.28
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/19 11:06 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
